ClinicalTrials.gg
RecruitingNCT07398859Updated Mar 27, 2026

Clinical Study on TQH2722 Injection Combined With Background Therapy for Seasonal Allergic Rhinitis

A Phase 2 interventional study of TQH2722 injection in Seasonal Allergic Rhinitis, sponsored by Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.. Recruiting at 30 sites in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-03-27.

Sponsored by Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd. (part of Sino Biopharmaceutical Limited) · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Started Mar 2026; still recruiting 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
300
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 27 studies in Rhinitis, Allergic, Seasonal with a site in China — 12 open to participants now, 14 under way, 8 of them phase 3. Rhinitis, Allergic, Seasonal · China.

Planned enrollment
8th of 27
300 · median 160
Started
2026
with 5 others
Phase 2
12 of 27
5 open now
Primary completion
2026-11
later than 9 of 13 live
Registered
22nd of 27
by date
Lead sponsor
2 of 27
Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.

Among the 27 studies in Rhinitis, Allergic, Seasonal with a site in China, this one is the 8th largest by planned enrollment, is one of 6 that started in 2026, is one of 12 in phase 2, reaches primary completion later than 9 of the 13 other live ones, and was the 22nd registered.

Rhinitis, Allergic, Seasonal

404 studies on the registry are indexed under Rhinitis, Allergic, Seasonal; 24 are open to participants now.

Browse Rhinitis, Allergic, Seasonal studies →

Open to participants now

12 of the 27 studies in Rhinitis, Allergic, Seasonal with a site in China are open now. Recruiting first, the newest first:

6 more — sign in →

All 12 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 17 Rhinitis, Allergic, Seasonal studies recruiting now, 2 (12%) set no upper age limit and 15 (88%) stop at 75 or younger; 1 takes children under 18; 5 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 27 studies in Rhinitis, Allergic, Seasonal with a site in China, or all of them as a file.
02

Study summary

This study is a multicenter, open-label, Phase II, single-arm clinical trial, with a planned enrollment of 200 to 300 subjects. Its primary objective is to evaluate the safety and efficacy of TQH2722 injection in the treatment of seasonal allergic rhinitis.

03

Conditions studied

  • Seasonal Allergic Rhinitis
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Aged 18-75, with no gender restrictions.
  • Diagnosed with seasonal allergic rhinitis.
  • Positive allergen test result.
  • The subjects have sufficient exposure to pollen during the pollen season.
  • The subject's medical history indicates that the subject had poor control of Seasonal Allergic Rhinitis (SAR) symptoms during the previous pollen season or the subject was dissatisfied with the subjective symptom control.
  • Screen for subjects who have a morning iTNSS score of ≥4 on the day of screening; at baseline visit, have a morning iTNSS score of ≥4, and have an average rTNSS score of ≥4 over the past 6 days.
  • Good compliance during screening/induction period.
  • Subjects with comorbid asthma should have stable medication use before the screening period and have their asthma condition assessed as stable by the investigator or specialist.
  • The subjects voluntarily joined this study, signed the form, and exhibited good compliance.
  • The subjects and their partners agree to take effective measures throughout the entire study period (from the signing of the Informed Consent Form (ICF) to 3 months after the last administration of the trial drug).

Exclusion criteria

Exclusion Criteria:

  • Any abnormal laboratory test value during the screening period or randomization.
  • Any disease that researchers consider to be unstable and may affect the patient's safety throughout the entire study period, or affect the study results or their interpretation, or hinder the patient's ability to complete the entire study process.
  • Patients with active diseases.
  • Known or suspected .
  • Subjects with active malignant tumors or a history of malignant tumors.
  • Screen for individuals with a history of active tuberculosis within the previous 12 months.
  • During the screening period, there is active hepatitis, or the presence of antibody (Anti-HIV) positivity, or syphilis treponema antibody (Anti-TP) positivity.
  • Screen for cases diagnosed with helminthic parasitic infections within the previous 6 months, who have not undergone standard treatment or have experienced ineffective standard treatment.
  • Subjects who have received specific medications or undergone any nasal or sinus surgery within the specified timeframe.
  • Intravenous immunoglobulin (IVIG) therapy and/or plasma exchange within 30 days before screening.
  • Screen subjects who have used monoamine oxidase inhibitors within the previous 14 days.
  • Initiate allergen immunotherapy within 3 months prior to screening.
  • Screen for individuals who have received attenuated within the previous 4 weeks or plan to receive attenuated live vaccines during the study period.
  • Screen for systemic Chinese herbal preparations used for the treatment of AR with short- or medium-acting systemic within 4 weeks, or screen for long-acting Systemic Corticosteroids (SCS) received within the previous 6 weeks.
  • Suffering from chronic active or acute infection within 2 weeks before screening or during the screening and import period.
  • Patients with concomitant asthma should be excluded if they meet any of the following conditions: a. (FEV1) ≤ 50% of the predicted normal value; b. acute exacerbation of asthma within 90 days prior to screening; c. currently using fluticasone propionate at a daily dose of >1000 μg/day or equivalent doses of other inhaled corticosteroids; d. assessed by the investigator or specialist as having unstable asthma.
  • The subject has a concomitant disease that renders them unable to complete the screening period assessment or evaluate the primary efficacy endpoint.
  • Suffering from malignant and benign tumors in the nasal cavity.
  • Subjects with perennial allergic rhinitis (PAR) who are allergic to pet hair.
  • Unable to use nasal corticosteroid sprays or antihistamines.
  • Have a history of systemic allergy to any biological agents.
  • Women who are pregnant or breastfeeding.
  • Individuals who abuse alcohol, use drugs, and have known drug dependency.
  • History of major organ transplantation or hematopoietic stem cell/bone marrow transplantation.
  • According to the researcher's judgment, there are any medical or psychiatric symptoms that may put the subjects at risk, interfere with their participation in the study, or interfere with the interpretation of the study results.
  • The forced expiratory volume in one second (FEV1) of the subject is less than or equal to 50% of the predicted normal value.
  • Other reasons why the researcher believes it is inappropriate to participate in this trial.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
300 participants (estimated)

Study arms

  • Experimental
    TQH2722 injection

    Injection combined with TQH2722, 2 weeks as a treatment cycle.

    Drug: TQH2722 injection

Interventions

  • TQH2722 injection is a humanized monoclonal antibody targeting interleukin-4 receptor alpha (IL-4Rα).

06

What researchers measure

Primary outcomes

  1. Number of subjects with incidence of adverse event

    Adverse events occurring during treatment.

    Time frame: Baseline up to 4 weeks

Secondary outcomes

  1. Number of subjects with incidence of serious adverse event

    Serious adverse event occurring during treatment.

    Time frame: Baseline up to 4 weeks

  2. Number of subjects with incidence of abnormality check indicators

    Number of subjects with incidence of abnormality check indicators: Abnormal examination indicators occurred during treatment.

    Time frame: Baseline up to 4 weeks

  3. Retrospective nasal symptom score after treatment for 2 weeks

    The average change in the retrospective total nasal symptom score (rTNSS) per day over 2 weeks of treatment compared to baseline. The total score is 0-12 points, with the higher score meaning the more severe symptoms.

    Time frame: Baseline up to 2 weeks

  4. Retrospective nasal symptom score after treatment for 4 weeks

    The average change in the retrospective total nasal symptom score (rTNSS) per day over 4 weeks of treatment compared to baseline. The total score is 0-12 points, with the higher score meaning the more severe symptoms.

    Time frame: Baseline up to 4 weeks

  5. Mean daily morning retrospective total nasal symptom score

    Mean change from baseline in the morning retrospective total nasal symptom score (AM rTNSS) at 2 weeks and 4 weeks of treatment. The total score is 0-12 points, with the higher score meaning the more severe symptoms.

    Time frame: Baseline up to 2 and 4 weeks

  6. Mean daily retrospective total nasal symptom score at night

    Mean change from baseline in the Post-Medication Reviewed Total Nasal Symptom Score (PMrTNSS) at night per day at 2 weeks and 4 weeks of treatment. The total score is 0-12 points, with the higher score meaning the more severe symptoms.

    Time frame: Baseline up to 2 and 4 weeks

  7. Total instantaneous nasal symptom score before medication in the morning every day

    Mean change from baseline in instantaneous total nasal symptom score (iTNSS) before medication administration in the morning, for each day during the 2-week and 4-week treatment periods. The total score is 0-12 points, with the higher score meaning the more severe symptoms.

    Time frame: Baseline up to 2 and 4 weeks

  8. Daily retrospective total nasal symptom score

    Mean percentage change from baseline in daily rTNSS at 2 weeks and 4 weeks of treatment.

    Time frame: Baseline up to 2 and 4 weeks

  9. Total instantaneous nasal symptom score before medication in the morning every day

    Mean percentage change from baseline in iTNSS before medication administration in the morning, for each day during the 2-week and 4-week treatment periods.

    Time frame: Baseline up to 2 and 4 weeks

  10. Daily retrospective scoring of individual nasal symptoms

    Mean change from baseline in daily retrospective nasal single symptom scores at 2 weeks and 4 weeks of treatment.

    Time frame: Baseline up to 2 and 4 weeks

  11. Daily retrospective nasal single symptom score during daytime

    Mean change from baseline in retrospective daytime (AM) nasal individual symptom scores (rhinorrhea, nasal congestion, nasal itch, and sneezing) at 2 weeks and 4 weeks of treatment.

    Time frame: Baseline up to 2 and 4 weeks

  12. Daily retrospective nasal single symptom score during night

    Mean change from baseline in retrospective nasal individual symptom (rhinorrhea, nasal congestion, nasal itch, and sneezing) scores at night (PM) at 2 weeks and 4 weeks of treatment.

    Time frame: Baseline up to 2 and 4 weeks

  13. Daily retrospective total score of ocular symptoms

    Mean change from baseline in the retrospective Total Ocular Symptom Score (rTOSS) at 2 weeks or 4 weeks of treatment.

    Time frame: Baseline up to 2 and 4 weeks

  14. Total score of retrospective ocular symptoms during daytime each day

    Mean change from baseline in the total daytime retrospective ocular symptom score (AM rTOSS) at 2 weeks and 4 weeks of treatment.

    Time frame: Baseline up to 2 and 4 weeks

  15. Total score of retrospective ocular symptoms each night

    The average change in the retrospective total ocular symptom score (PM rTOSS) at night compared to baseline after 2 weeks and 4 weeks of treatment.

    Time frame: Baseline up to 2 and 4 weeks

  16. Total score of instantaneous ocular symptoms before medication in the morning every day

    Mean change from baseline in instantaneous total ocular symptom score (iTOSS) before medication administration in the morning, at 2 weeks and 4 weeks of treatment.

    Time frame: Baseline up to 2 and 4 weeks

  17. Daily retrospective total score of ocular symptoms

    Mean percentage change in total retrospective ocular symptom score from baseline at 2 weeks and 4 weeks of treatment, respectively.

    Time frame: Baseline up to 2 and 4 weeks

  18. Total score of instantaneous ocular symptoms before medication each morning

    Mean percentage change from baseline in total ocular symptom score immediately before medication administration in the morning, for the 2-week and 4-week treatment periods.

    Time frame: Baseline up to 2 and 4 weeks

  19. Daily retrospective scoring of individual ocular symptoms

    Mean change in individual ocular symptom scores from baseline to 2 weeks and 4 weeks after treatment, retrospectively assessed daily.

    Time frame: Baseline up to 2 and 4 weeks

  20. Daily retrospective scoring of individual ocular symptoms during the day

    Mean change from baseline in retrospective ocular symptom scores during daytime (AM) on each day at 2 weeks and 4 weeks of treatment.

    Time frame: Baseline up to 2 and 4 weeks

  21. Nightly retrospective scoring of individual ocular symptoms

    Mean change from baseline in retrospective ocular symptom scores at night (PM) at 2 weeks and 4 weeks of treatment

    Time frame: Baseline up to 2 and 4 weeks

  22. Quality of Life Questionnaire Score for Patients with Allergic Rhinitis

    The change in Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ) scores from baseline for patients with allergic rhinitis after 2 weeks and 4 weeks of treatment.

    Time frame: Baseline up to 2 and 4 weeks

  23. Daily retrospective total score of nasal symptoms

    The area under the curve representing the average change in the retrospective total nasal symptom score (rTNSS) from baseline, calculated for each day during the 2-week and 4-week treatment periods.

    Time frame: Baseline up to 2 and 4 weeks

  24. Blood eosinophil count and percentage

    Changes in eosinophil count and percentage from baseline, as well as the percentage of change, at each evaluation visit point.

    Time frame: Baseline up 12 weeks

  25. Serum total immunoglobulin E concentration

    The changes in serum total immunoglobulin E concentration and the percentage of change from baseline at each evaluation visit point.

    Time frame: Baseline up 12 weeks

  26. Forced expiratory volume in 1 second (FEV1) before bronchodilator administration (BD) in subjects with concomitant asthma

    The change in forced expiratory volume in one second (FEV1) relative to baseline before the use of bronchodilator (BD) in subjects with asthma across all visit points.

    Time frame: Baseline up 12 week

07

Study locations

3 of 30 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2026 (actual). Primary completion is estimated for Nov 2026, 8 months after the start.

Of 24 phase 2 interventional studies under Rhinitis, Allergic, Seasonal, half reached primary completion within 5 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 23. This study's planned 8 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 3, 2026
First posted
Feb 10, 2026
StartActual
Mar 19, 2026
Primary completionEst.
Nov 2026
CompletionEst.
Mar 2027
Last update
Mar 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 27, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07398859
Responsible party
Sponsor
First posted
Feb 10, 2026
Start date
Mar 19, 2026
Primary completion
Nov 2026 (estimated)
Completion
Mar 2027 (estimated)
Last update
Mar 27, 2026

Study contacts

Zheng Liu, Doctor
Contact
zhengliuent@hotmail.com
18607110505
Rongfei Zhu, Doctor
Contact
zrf13092@163.com
18986292602

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: TQH2722

Start the discussion